Poolbeg Pharma FY Results:“ we’ve selected our development processes to be very cost efficient”
Episode 1872, Apr 30, 07:49 AM
Jeremy Skillington, CEO of Poolbeg Pharma (POLB) talks Vox Markets through a landmark year that has seen the innovative biopharma company make huge strides progressing its treatments, opening up new markets, and strengthening its team - all whilst retaining its strong balance sheet thanks to disciplined capital allocation.